REGN3918
R3918-PNH-1852
Phase 2 small_molecule completed
Quick answer
REGN3918 for Paroxysmal Nocturnal Hemoglobinuria (PNH) is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed